Some problems with posttransplant lymphoproliferative disease

Transplantation

Volumn 69, Issue 5, 2000, Pages 705-706

  Penn, Israel ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

COHORT ANALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; NOTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0034654062     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00002     Document Type: Note

References (5)

1. Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998; 20: 343.
2. Penn I. De novo cancers in organ allograft recipients. Curr Opin Org Transplant 1998; 3: 188.
3. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2: 33.
4. McDiarmid SV, Jordon S, Lee G, et al. Prevention and pre-emptive therapy of post-transplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 12: 1604.
5. Dotti G, Fiocchi R, Motta T, et al. EBV-negative lymphoproliferative disorders in long term survivors after heart, kidney and liver transplant. Transplantation 2000; 69: 827.